What is the address of BioScientific Group?

The registered office of BioScientific Group is located at Avenue Zénobe Gramme 38, 1300 Wavre.

Is BioScientific Group still active?

Yes. According to the CBE (29 October 2026) BioScientific Group is active, legal situation “Normale toestand”, started on 12 December 2019.

Is BioScientific Group registered on Peppol?

Yes, BioScientific Group is registered on the Peppol network with ID 0208:0739510875.

What is the enterprise number of BioScientific Group?

The enterprise number of BioScientific Group is BE0739510875.

When was BioScientific Group founded?

BioScientific Group was founded on 12 December 2019.

Who are the directors of BioScientific Group?

According to the 2025 annual accounts, the directors of BioScientific Group are: Lead Ventures SRL.

Is BioScientific Group a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 December 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did BioScientific Group make in 2025?

BioScientific Group posted a profit after taxes of € 2,338,298 in financial year 2025.

What is the revenue of BioScientific Group?

As a small company, BioScientific Group is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 81,539.

How many employees does BioScientific Group have?

According to the 2025 annual accounts, BioScientific Group has 0 full-time equivalents (FTE).

BioScientific Group (Private Limited) - Wavre

Q: What does BioScientific Group do?

BioScientific Group is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 12 December 2019, 1 establishment.

Dossier BioScientific Group, printed on 29 October 2026 from databakkes.be/en/0739510875/bioscientific-group. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 6 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

BioScientific Group from Wavre, company number BE0739510875, closed financial year 2025 with a result of € 2.3 million after tax. For that financial year BioScientific Group recorded a gross margin of € 81,539 and equity of € 6.1 million. Compared with financial year 2024, the result moved from € -100,555 to € 2.3 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 25, 2026.

What it is worth Growing

€ 6.1 million

▲ 56% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 2.3 million

▲ still € 100,555 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,125

▼ 98% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 139,084 paid out

6 % of the profit went to the shareholders, mostly to Lead Ventures (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.5 million

▼ 21% vs 2024

€ 926,920 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 34,473

▼ 10% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 4,542

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2024	2025	Change 2024 → 2025
Gross margin	€ 78,879 Gross margin 2023: € 78,879 First fiscal year in the series	€ -9,305 Gross margin 2024: € -9,305 ▼ € 88,184 vs 2023 (€ 78,879) Unfavourable step	€ 33,216 Gross margin 2024: € 33,216 ▲ € 42,521 vs 2024 (€ -9,305) Favourable step	€ 81,539 Gross margin 2025: € 81,539 ▲ 145% vs 2024 (€ 33,216) Favourable step	▲ 145%
Profit after taxes	€ 1,825,278 Profit after taxes 2023: € 1,825,278 First fiscal year in the series	€ 1,211,124 Profit after taxes 2024: € 1,211,124 ▼ 34% vs 2023 (€ 1,825,278) Unfavourable step	€ -100,555 Profit after taxes 2024: € -100,555 ▼ € 1.3 million vs 2024 (€ 1,211,124) Unfavourable step	€ 2,338,298 Profit after taxes 2025: € 2,338,298 ▲ € 2.4 million vs 2024 (€ -100,555) Favourable step	▲ € 2.4 million
Equity	€ 2,895,661 Equity 2023: € 2,895,661 First fiscal year in the series	€ 4,106,784 Equity 2024: € 4,106,784 ▲ 42% vs 2023 (€ 2,895,661) Favourable step	€ 3,943,383 Equity 2024: € 3,943,383 ▼ 4% vs 2024 (€ 4,106,784) Unfavourable step	€ 6,142,597 Equity 2025: € 6,142,597 ▲ 56% vs 2024 (€ 3,943,383) Favourable step	▲ 56%
Total debts	€ 4,776,414 Total debts 2023: € 4,776,414 First fiscal year in the series	€ 9,621,706 Total debts 2024: € 9,621,706 ▲ 101% vs 2023 (€ 4,776,414) Unfavourable step	€ 9,723,702 Total debts 2024: € 9,723,702 ▲ 1% vs 2024 (€ 9,621,706) Unfavourable step	€ 7,479,912 Total debts 2025: € 7,479,912 ▼ 23% vs 2024 (€ 9,723,702) Favourable step	▼ 23%
Cash	€ 112,568 Cash 2023: € 112,568 First fiscal year in the series	€ 112,264 Cash 2024: € 112,264 Unchanged (€ 112,568) Unfavourable step	€ 145,698 Cash 2024: € 145,698 ▲ 30% vs 2024 (€ 112,264) Favourable step	€ 3,125 Cash 2025: € 3,125 ▼ 98% vs 2024 (€ 145,698) Unfavourable step	▼ 98%
Retained profit	€ 2,395,661 Retained profit 2023: € 2,395,661 First fiscal year in the series	€ 3,606,784 Retained profit 2024: € 3,606,784 ▲ 51% vs 2023 (€ 2,395,661) Favourable step	€ 3,443,383 Retained profit 2024: € 3,443,383 ▼ 5% vs 2024 (€ 3,606,784) Unfavourable step	€ 5,642,597 Retained profit 2025: € 5,642,597 ▲ 64% vs 2024 (€ 3,443,383) Favourable step	▲ 64%
Dividend	€ 0 Dividend 2023: € 0 First fiscal year in the series	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 62,847 Dividend 2024: € 62,847 Unchanged (€ 0) Unchanged	€ 139,084 Dividend 2025: € 139,084 ▲ 121% vs 2024 (€ 62,847) Unchanged	▲ 121%
Bank debt	€ 3,829,103 Bank debt 2023: € 3,829,103 First fiscal year in the series	€ 6,441,387 Bank debt 2024: € 6,441,387 ▲ 68% vs 2023 (€ 3,829,103) Unfavourable step	€ 4,489,245 Bank debt 2024: € 4,489,245 ▼ 30% vs 2024 (€ 6,441,387) Favourable step	€ 3,531,069 Bank debt 2025: € 3,531,069 ▼ 21% vs 2024 (€ 4,489,245) Favourable step	▼ 21%
Balance sheet total	€ 7,672,075 Balance sheet total 2023: € 7,672,075 First fiscal year in the series	€ 13,728,490 Balance sheet total 2024: € 13,728,490 ▲ 79% vs 2023 (€ 7,672,075) Unchanged	€ 13,667,085 Balance sheet total 2024: € 13,667,085 Unchanged (€ 13,728,490) Unchanged	€ 13,622,509 Balance sheet total 2025: € 13,622,509 Unchanged (€ 13,667,085) Unchanged

Key figures of BioScientific Group, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BioScientific Group?

What happened at BioScientific Group in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 25, 2026 New annual accounts for financial year 2025: profit of € 2.3 million. filed late Source: NBB ↗
Jan 1, 2020 New establishment in Wavre. KBO
2019 Lead Ventures SRL became a director. NBB
Dec 12, 2019 Start of the company according to the CBE. KBO

In short

From € 1.8 million profit in 2023 to € 2.3 million profit in 2025.

Best year ever: 2025, with € 2.3 million profit.

Paid out € 201,931 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Lead Ventures 100%

The stake of Lead Ventures comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BioScientific Group

Barré 100%

R-Concept 100%

Behind BioScientific Group is Lead Ventures SRL. The shares are held by Lead Ventures (100%). It owns 100% of Barré and 100% of R-Concept itself.

Directors

According to the 2025 annual accounts

Lead Ventures SRL

Director · represented by Javier MARTINEZ

Also active at: IDEATEC, COPIA Invest SRL

since 2019

Shareholders

Lead Ventures

100%

Participations

Barré

100%

R-Concept

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Zénobe Gramme 38

1300 Wavre

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Barré same network

€ 3.4 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0739.510.875

VAT number

BE 0739.510.875

Registered office

Avenue Zénobe Gramme 38, 1300 Wavre

Names & denominations

BioScientific Group · BSG

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 December 2019

Peppol

Active · Active since 30 Jun 2026

Contact

[email protected]

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

BioScientific Group

Warning lights

Financials

What happened to BioScientific Group?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions